Analyst Price Targets — VIR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 11:41 am | Patrick Trucchio | H.C. Wainwright | $20.00 | $9.13 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright |
| February 26, 2026 6:07 pm | Roanna Ruiz | Leerink Partners | $20.00 | $9.33 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners |
| February 24, 2026 7:22 pm | — | Barclays | $30.00 | $9.49 | TheFly | Vir Biotechnology price target raised to $30 from $26 at Barclays |
| February 24, 2026 1:02 pm | Cory Kasimov | Evercore ISI | $18.00 | $9.70 | TheFly | Vir Biotechnology price target raised to $18 from $12 at Evercore ISI |
| February 24, 2026 12:05 pm | Joseph Stringer | Needham | $18.00 | $9.64 | StreetInsider | Vir Biotechnology (VIR) PT Raised to $18 at Needham |
| February 24, 2026 11:49 am | Michael Ulz | Morgan Stanley | $24.00 | $7.43 | TheFly | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley |
| February 24, 2026 11:05 am | Sean McCutcheon | Raymond James | $19.00 | $9.69 | StreetInsider | Raymond James Upgrades Vir Biotechnology (VIR) to Strong Buy |
| February 17, 2026 11:36 am | — | Barclays | $26.00 | $7.47 | TheFly | Vir Biotechnology price target raised to $26 from $24 at Barclays |
| February 4, 2026 10:46 am | Etzer Darout | Barclays | $24.00 | $7.68 | TheFly | Vir Biotechnology price target lowered to $24 from $31 at Barclays |
| December 30, 2025 11:38 am | Patrick Trucchio | H.C. Wainwright | $15.00 | $5.98 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR) |
Latest News for VIR
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston,…
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross…
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to…
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and…
Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VIR.
U.S. House Trading
No House trades found for VIR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.